PAPAartis version 3.0

  • Research type

    Research Study

  • Full title

    Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Staged Segmental Artery Coil- Embolization’: A Randomized Controlled Multicentre Trial

  • IRAS ID

    230945

  • Contact name

    Aung Ye Oo

  • Contact email

    AungYe.OO@Bartshealth.nhs.uk

  • Sponsor organisation

    University Leipzig, University Hospital for Heart Surgery

  • Clinicaltrials.gov Identifier

    NCT03434314

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    Based on statistics from the USA, one can estimate that 7,500 people per 100 Mio are diagnosed annually with an aortic aneurysm. Left untreated, the prognosis is very poor, since internal bleeding due to a rupture of the aneurysm brings about sudden death. If diameters have reached 60 mm, mortality is estimated to be 11%/year.
    The repair of aortic aneurysms based on conventional stenting techniques have achieved a remarkable decrease in the incidence of paraplegia and paraparesis, but they still constitute an incidence of up to 20%.
    At present there is a tremendous need for state of the art and safe strategies for aortic repair which prevent paraplegia - an individual disaster with profound impact on long-term outcome and health care cost.
    The proposed clinical trial will support a proof of concept in humans to assess the clinical efficacy of a novel therapeutic concept: Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Staged Segmental Artery coil-Embolization’ (MIS2ACE) to prevent paraplegia.

  • REC name

    London - Bromley Research Ethics Committee

  • REC reference

    21/LO/0406

  • Date of REC Opinion

    26 May 2021

  • REC opinion

    Unfavourable Opinion